I like this from the BioPharm Catalyst newsletter six hours ago

[jayfish101]

Key PDUFA and regulatory catalysts for the next 6 months
This week marks the continuation of our six-month monitoring period, where we expect to see more than 500 significant catalysts. Importantly, 61 of these are currently in the regulatory phase, pending decisions from the FDA. In today’s update, we will spotlight a few key upcoming catalysts. Next week, we plan to update our watchlist to concentrate on key Catalysts due by Mid-2024.

Geron Corporation (NASDAQ: GERN) is a clinical-stage biopharmaceutical company focused on the development of its sole candidate, imetelstat, for the treatment of hematologic malignancies. Imetelstat is currently under review for myelodysplastic syndromes (MDS), and the Prescription Drug User Fee Act (PDUFA) date is set for June 16, 2024. This follows a positive advisory committee vote, which generally bodes well for final approval prospects. With a market capitalization of approximately $1.63 billion and robust trading volumes, Geron presents as a relatively mature player in the field of biotechnology focused on oncology. The potential approval of imetelstat could significantly impact the company's future, given the substantial unmet medical need and the lack of effective treatments currently available for MDS.